SIGLEC15 and invasive breast carcinoma: The upregulation of SIGLEC15 was linked to longer overall survival in bladder urothelial carcinoma, breast invasive carcinoma, head and neck squamous cell carcinoma, thyroid carcinoma, and uterine corpus endometrial carcinoma, and longer relapse-free survival in breast invasive carcinoma, liver hepatocellular carcinoma, ovarian serous cystadenocarcinoma, and uterine corpus endometrial carcinoma (27).